- YERVOY is First and Only Approved Therapy for Unresectable or Metastatic Melanoma to Demonstrate a Significant Improvement in Overall Survival
- R&D Productivity Continues with Positive EU Advisory Opinions for ELIQUIS™ (apixaban) for VTE Prevention and NULOJIX™ (belatacept), and Robust Data from Hepatitis C Portfolio
- Sales Increase 4% to $5.0 Billion in First Quarter
- GAAP EPS Increases 33% to $0.57; Non-GAAP EPS Increases 4% to $0.58 in First Quarter
- Company Confirms 2011 GAAP EPS Guidance Range of $2.00 to $2.10; Non-GAAP Guidance Range of $2.10 to $2.20
NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced first quarter results that included strong sales and earnings growth, and several key R&D milestones—most notably U.S. regulatory approval for YERVOY. The company also confirmed guidance for the year.
“The strength of our financial and R&D performance in the first quarter confirms our ability to execute our focused BioPharma strategy and helps position us for long-term success,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb.
“Our string of achievements in the quarter is a good start to an exciting year in which we are anticipating several key regulatory decisions and the presentation of important data across our portfolio. We delivered solid financial performance at both the top and bottom lines, received regulatory approval for YERVOY in the U.S., received a positive advisory opinion from European regulatory authorities for both ELIQUIS and NULOJIX, and presented promising data on our investigational hepatitis C portfolio at the annual meeting of the European Association for the Study of the Liver,” Andreotti said.
| First Quarter | ||||||||||
| $ amounts in millions, except per share amounts | ||||||||||
| 2011 | 2010 | Change | ||||||||
| Net Sales | $ | 5,011 | $ | 4,807 | 4 | % | ||||
| GAAP Diluted EPS | 0.57 | 0.43 | 33 | % | ||||||
| Non-GAAP Diluted EPS | 0.58 | 0.56 | 4 | % | ||||||
FIRST QUARTER FINANCIAL RESULTS
- Bristol-Myers Squibb posted first quarter 2011 net sales of $5.0 billion.
- U.S. net sales increased 5% to $3.3 billion in the first quarter of 2011 compared to the same period in 2010. International net sales increased 3%, or 1% excluding foreign exchange impact, to $1.8 billion.
- Gross margin as a percentage of net sales was 73.2% in the first quarter of 2011 compared to 72.8% in the same period in 2010.
- Marketing, selling and administrative expenses increased 3% to $928 million in the first quarter of 2011.
- Advertising and product promotion spending increased 1% to $214 million in the first quarter of 2011.
- Research and development expenses increased 3% to $935 million in the first quarter of 2011.
- The effective tax rate on earnings before income taxes was 22.6% on a GAAP basis in the first quarter of 2011, compared to 24.2% in the same period in 2010.
- The Company reported GAAP net earnings attributable to Bristol-Myers Squibb of $986 million, or $0.57 per share, in the first quarter of 2011 compared to $743 million or $0.43 per share for the same period in 2010.
- The Company reported non-GAAP net earnings of $1.0 billion, or $0.58 per share, in the first quarter of 2011 compared to $967 million, or $0.56 per share, for the same period in 2010. An overview of specified items is discussed under the “Use of Non-GAAP Financial Information” section.
- The incremental impact of the two additional U.S. health care reform provisions for new discounts associated with the Medicare Part D coverage gap and an annual pharmaceutical company fee decreased first quarter EPS by approximately $0.03 on both a GAAP and non-GAAP basis.
- Cash, cash equivalents and marketable securities were $9.9 billion, with a net cash position of $4.4 billion as of March 31, 2011.
FIRST QUARTER PRODUCT AND PIPELINE UPDATE
- Bristol-Myers Squibb’s global sales growth in the first quarter was led by PLAVIX® (6%), recently launched ONGLYZA® and KOMBIGLYZE™, BARACLUDE® (27%), SPRYCEL® (31%) and ORENCIA® (18%).
YERVOY
- In March, the U.S. Food and Drug Administration (FDA) approved YERVOY for the treatment of patients with newly diagnosed or previously-treated unresectable (inoperable) or metastatic melanoma. YERVOY became commercially available in the U.S. in early April.
- In March, the Company announced that a Phase III clinical trial of YERVOY—known as study 024—met its primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. An abstract of the 024 data was submitted to the American Society of Clinical Oncology for potential presentation at its Annual Meeting in June.
ELIQUIS
- In February, the Company and its partner, Pfizer, announced that AVERROES data demonstrating that the investigational agent ELIQUIS was superior to aspirin in reducing stroke or systemic embolism in patients with atrial fibrillation unsuitable for warfarin was published in The New England Journal of Medicine. Preliminary results of AVERROES were first presented in August 2010 at the European Society of Cardiology annual meeting in Stockholm. Full results were presented at the International Stroke Conference in February 2011 in Los Angeles.
- In March, the Marketing Authorization Application (MAA) for ELIQUIS received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for use in the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery. The CHMP’s positive opinion will now be reviewed by the European Commission, which has authority to approve medicines for the European Union.
NULOJIX
- In April, the MAA for NULOJIX received a positive opinion from the CHMP for use in adult patients receiving kidney transplants. The positive opinion is subject to review by the European Commission.
Dapagliflozin
- In March, the FDA accepted for review the New Drug Application (NDA) for dapagliflozin for the treatment of adults with type 2 diabetes. The Prescription Drug User Fee Act (PDUFA) date—the date by which action from the FDA is expected—is October 28, 2011. The company develops dapagliflozin with its partner AstraZeneca.
PLAVIX
- In January, the FDA granted an additional six-month period of exclusivity to market PLAVIX. Exclusivity for PLAVIX is now scheduled to expire May 17, 2012. The Company develops and commercializes PLAVIX with its partner sanofi-aventis.
ONGLYZA
- In February, the Company and its partner, AstraZeneca, announced that the FDA approved a labeling update for ONGLYZA to include data from two clinical studies. The U.S. label update provides more evidence regarding the use of ONGLYZA in renally impaired adults with type 2 diabetes, and more information on the comparison between glipizide and ONGLYZA in patients also taking metformin. Data from the renal study also led to approval by the European Commission for the use of ONGLYZA in treating people with type 2 diabetes who have moderate or severe renal impairment.
- In February, the FDA approved ABILIFY as an adjunct to mood stabilizers lithium or valproate for the maintenance treatment of Bipolar I Disorder. European approval for this use was received in January. The Company develops and commercializes ABILIFY with its partner Otsuka.
BARACLUDE
- In March, the European Commission approved BARACLUDE for the treatment of hepatitis B in adult patients with decompensated liver disease.
Necitumumab
- In February, the Company and its partner, Eli Lilly, stopped enrollment in one of two Phase III studies evaluating necitumumab as a first-line treatment for advanced nonsquamous non-small cell lung cancer, based on recommendations from an independent Data Monitoring Committee (DMC). Necitumumab continues to be studied in a Phase III trial evaluating its potential as a treatment for a different type of lung cancer called squamous non-small cell lung cancer, based on recommendations from the same DMC.
Investigational Hepatitis C (HCV) Portfolio
- In March, at the International Liver Congress, the annual meeting of the European Association for the Study of the Liver (EASL), the Company presented data on investigational compounds in HCV, including: BMS-790052, a direct acting antiviral NS5A replication complex inhibitor; and PEG-Interferon lambda.
BUSINESS DEVELOPMENT UPDATE
In March, the Company and WuXi PharmaTech announced a partnership under which WuXi will build, equip and operate a dedicated fully cGMP-compliant 25,000-square-foot analytical testing facility in Shanghai to store and test stability samples of small-molecule new chemical entities to support global marketing applications.
2011 FINANCIAL GUIDANCE
Bristol-Myers Squibb is confirming its 2011 GAAP EPS guidance range from $2.00 to $2.10 and its non-GAAP EPS range from $2.10 to $2.20. Key 2011 non-GAAP guidance assumptions remain unchanged. The non-GAAP guidance excludes specified items as discussed under “Use of Non-GAAP Financial Information.” Details reconciling adjusted non-GAAP amounts with the amounts reflecting specified items are provided in supplemental materials available on the Company’s website.
The financial guidance for 2011 excludes the impact of any potential strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified.
Use of Non-GAAP Financial Information
This press release contains non-GAAP financial measures, including non-GAAP earnings from continuing operations and related earnings per share information, adjusted to exclude certain costs, expenses, significant gains and losses and other specified items. Among the items in GAAP measures but excluded for purposes of determining adjusted earnings and other adjusted measures are: restructuring and other exit costs; accelerated depreciation charges; asset and IPRD impairments; charges and recoveries relating to significant legal proceedings; upfront, milestone and other licensing payments for in-licensing of products that have not achieved regulatory approval which are immediately expensed; and significant tax events. This information is intended to enhance an investor’s overall understanding of the company’s past financial performance and prospects for the future. For example, non-GAAP earnings and earnings per share information is an indication of the company’s baseline performance before items that are considered by the company not to be reflective of the company’s ongoing results. In addition, this information is among the primary indicators the company uses as a basis for evaluating company performance, allocating resources, setting incentive compensation targets, and planning and forecasting of future periods. This information is not intended to be considered in isolation or as a substitute for net earnings or diluted earnings per share prepared in accordance with GAAP.
Statement on Cautionary Factors
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, implementation of the new discounts and new pharmaceutical company fee under the 2010 U.S. health care reform law, governmental laws and regulations related to Medicare, Medicaid, Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, the inability to improve or remediate FDA concerns raised in the warning letter regarding certain GMP processes at our Manati facility, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including the Avalide recall and extended supply shortage and any potential future recalls, patent positions and the ultimate outcome of any litigation matter. These factors also include the company’s ability to execute successfully its strategic plans, including its String of Pearls strategy, the expiration of patents or data protection on certain products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Company and Conference Call Information
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
There will be a conference call on April 28, 2011, at 10:30 a.m. EDT during which company executives will address inquiries from investors and analysts. Investors and the general public are invited to listen to a live web cast of the call at http://investor.bms.com or by dialing: 913-312-0732, confirmation code: 7584294. Materials related to the call will be available at the same website prior to the call.
| ABILIFY® is the trademark of Otsuka Pharmaceutical Co., Ltd. |
| ATRIPLA® is a trademark of both Bristol-Myers Squibb Co. and Gilead Sciences, Inc. |
| AVAPRO®, AVALIDE®, and PLAVIX® are trademarks of sanofi-aventis. |
| ERBITUX® is a trademark of ImClone LLC. ImClone Systems is a wholly-owned subsidiary of Eli Lilly and Company. |
| ELIQUIS™ is a trademark of Pfizer, Inc. |
| All other brand names of products appearing in all capital letters are registered trademarks of the Company or one of its subsidiaries. |
| BRISTOL-MYERS SQUIBB COMPANY |
| SELECTED PRODUCTS |
| FOR THE THREE MONTHS ENDED MARCH 31, 2011 AND 2010 |
| (Unaudited, dollars in millions) |
The following table sets forth worldwide and U.S. reported net sales for selected products. In addition, the table includes, where applicable, the estimated total U.S. prescription change for the retail and mail-order channels for the comparative periods presented for certain of the company's U.S. pharmaceutical products based on third-party data. A significant portion of the company's U.S. pharmaceutical sales is made to wholesalers. Where changes in reported net sales differ from prescription growth, this change in net sales may not reflect underlying prescriber demand.
|
Worldwide Net Sales |
U.S. Net Sales |
||||||||||||||||||||
|
2011 |
2010 |
% Change |
2011 |
2010 |
% Change |
% Change in U.S. Total |
|||||||||||||||
|
Three Months Ended March 31, |
|||||||||||||||||||||
|
Key Products |
|||||||||||||||||||||
| Plavix | $ | 1,762 | $ | 1,666 | 6 | % | 1,641 | $ | 1,531 | 7 | % | (4 | )% | ||||||||
| Avapro/Avalide | 290 | 314 | (8 | )% | 160 | 186 | (14 | )% | (32 | )% | |||||||||||
| Abilify | 624 | 617 | 1 | % | 460 | 470 | (2 | )% | 5 | % | |||||||||||
| Reyataz | 366 | 373 | (2 | )% | 181 | 186 | (3 | )% | 1 | % | |||||||||||
| Sustiva Franchise | 343 | 335 | 2 | % | 215 | 214 | — | 8 | % | ||||||||||||
| Baraclude | 275 | 216 | 27 | % | 48 | 42 | 14 | % | 11 | % | |||||||||||
| Erbitux | 165 | 166 | (1 | )% | 162 | 163 | (1 | )% | N/A | ||||||||||||
| Sprycel | 172 | 131 | 31 | % | 61 | 38 | 61 | % | 9 | % | |||||||||||
| Orencia | 199 | 169 | 18 | % | 138 | 126 | 10 | % | N/A | ||||||||||||
| Onglyza/Kombiglyze | 81 | 10 | * | 57 | 6 | * | * | ||||||||||||||
| Mature Products and All Other | 734 | 810 | (9 | )% | 127 | 127 | — | N/A | |||||||||||||
|
* In excess of +/- 200%. |
|||||||||||||||||||||
|
BRISTOL-MYERS SQUIBB COMPANY |
|||||||||
|
CONSOLIDATED STATEMENTS OF EARNINGS |
|||||||||
|
FOR THE THREE MONTHS ENDED MARCH 31, 2011 AND 2010 |
|||||||||
|
(Unaudited, amounts in millions except per share data) |
|||||||||
|
Three Months |
|||||||||
|
2011 |
2010 |
||||||||
| Net Sales | $ | 5,011 | $ | 4,807 | |||||
| Cost of products sold | 1,343 | 1,306 | |||||||
| Marketing, selling and administrative | 928 | 900 | |||||||
| Advertising and product promotion | 214 | 212 | |||||||
| Research and development | 935 | 910 | |||||||
| Provision for restructuring, net | 44 | 11 | |||||||
| Equity in net income of affiliates | (82 | ) | (97 | ) | |||||
| Other (income)/expense, net | (138 | ) | 113 | ||||||
| Total expenses | 3,244 | 3,355 | |||||||
|
|
1,767 | 1,452 | |||||||
| Provision for income taxes | 400 | 351 | |||||||
|
Net Earnings |
1,367 | 1,101 | |||||||
| Net Earnings Attributable to Noncontrolling Interest | 381 | 358 | |||||||
| Net Earnings Attributable to BMS | $ | 986 | $ | 743 | |||||
| Earnings per Common Share Attributable to BMS: | |||||||||
| Basic | $ | 0.58 | $ | 0.43 | |||||
| Diluted | $ | 0.57 | $ | 0.43 | |||||
| Average Common Shares Outstanding: | |||||||||
| Basic | 1,702 | 1,715 | |||||||
| Diluted | 1,714 | 1,725 | |||||||
| Other (income)/expense | |||||||||
|
Interest expense |
$ | 31 | $ | 33 | |||||
| Interest income | (21 | ) | (15 | ) | |||||
| Impairment and loss on sale of manufacturing operations | — | 200 | |||||||
| Loss/(Gain) on debt repurchase | (8 | ) | — | ||||||
| Net foreign exchange transaction losses/(gains) | (7 | ) | (16 | ) | |||||
| Gain on sale of product lines, businesses and assets | (9 | ) | (10 | ) | |||||
| Other income from alliance partners | (20 | ) | (50 | ) | |||||
| Pension curtailment and settlement charges | (3 | ) | — | ||||||
| Litigation recoveries | (102 | ) | — | ||||||
| Product liability charges | 26 | — | |||||||
| Other | (25 | ) | (29 | ) | |||||
| Other (income)/expense | $ | (138 | ) | $ | 113 | ||||
|
BRISTOL-MYERS SQUIBB COMPANY |
|||||||||||||||||||||
|
SPECIFIED ITEMS |
|||||||||||||||||||||
|
FOR THE THREE MONTHS ENDED MARCH 31, 2011 AND 2010 |
|||||||||||||||||||||
|
(Unaudited, dollars in millions) |
|||||||||||||||||||||
|
Three months ended March 31, 2011 |
|||||||||||||||||||||
|
Cost of |
Marketing, |
Research |
Provision |
Other |
Total |
||||||||||||||||
|
Restructuring Activity: |
|||||||||||||||||||||
|
Downsizing and streamlining of worldwide operations |
$ | -- | $ | -- | $ | -- | $ | 44 | $ | -- | $ | 44 | |||||||||
| Accelerated depreciation, asset impairment and | |||||||||||||||||||||
| other shutdown costs | 23 | -- | -- | -- | -- | 23 | |||||||||||||||
| Process standardization implementation costs | -- | 4 | -- | -- | -- | 4 | |||||||||||||||
| Total Restructuring | 23 | 4 | -- | 44 | -- | 71 | |||||||||||||||
| Other: | |||||||||||||||||||||
| Litigation charges/(recoveries), net | -- | -- | -- | -- | (102 | ) | (102 | ) | |||||||||||||
| Upfront, milestone and other licensing payments | -- | -- | 88 | -- | -- | 88 | |||||||||||||||
| IPRD Impairment | -- | -- | 15 | -- | -- | 15 | |||||||||||||||
| Product liability charges | -- | -- | -- | -- | 26 | 26 | |||||||||||||||
| Total | $ | 23 | $ | 4 | $ | 103 | $ | 44 | $ | (76 | ) | 98 | |||||||||
| Income taxes on items above | (28 | ) | |||||||||||||||||||
| Specified tax benefit | (56 | ) | |||||||||||||||||||
| Decrease to Net Earnings | $ | 14 | |||||||||||||||||||
|
Three months ended March 31, 2010 |
||||||||||||||||||||
|
Cost of |
Marketing, |
Research |
Provision |
Other |
Total |
|||||||||||||||
|
Restructuring Activity: |
||||||||||||||||||||
|
Downsizing and streamlining of worldwide operations |
$ | -- | $ | -- | $ | -- | $ | 11 | $ | -- | $ | 11 | ||||||||
| Impairment and loss on sale of manufacturing operations | -- | -- | -- | -- | 200 | 200 | ||||||||||||||
| Accelerated depreciation, asset impairment and | ||||||||||||||||||||
| other shutdown costs | 31 | -- | -- | -- | -- | 31 | ||||||||||||||
| Process standardization implementation costs | -- | 13 | -- | -- | -- | 13 | ||||||||||||||
| Total Restructuring | 31 | 13 | -- | 11 | 200 | 255 | ||||||||||||||
| Other: | ||||||||||||||||||||
|
Upfront, milestone and other licensing payments |
-- | -- | 55 | -- | -- | 55 | ||||||||||||||
| Total | $ | 31 | $ | 13 | $ | 55 | $ | 11 | $ | 200 | 310 | |||||||||
| Income taxes on items above | (86 | ) | ||||||||||||||||||
| Decrease to Net Earnings | $ | 224 | ||||||||||||||||||
|
BRISTOL-MYERS SQUIBB COMPANY |
|||||||||||||||||||||||
|
RECONCILIATION OF GAAP RESULTS |
|||||||||||||||||||||||
|
TO NON-GAAP RESULTS |
|||||||||||||||||||||||
|
FOR THE THREE MONTHS ENDED MARCH 31, 2011 AND 2010 |
|||||||||||||||||||||||
|
(Unaudited, amounts in millions except per share data) |
|||||||||||||||||||||||
| Q1 2011 | Q1 2010 | ||||||||||||||||||||||
| GAAP | Specified Items* |
Non GAAP |
GAAP | Specified Items* |
Non GAAP |
||||||||||||||||||
| Net Sales | $ | 5,011 |
-- |
$ | 5,011 | $ | 4,807 | -- | $ | 4,807 | |||||||||||||
| Cost of Products Sold | 1,343 | (23 | ) | 1,320 | 1,306 | (31 | ) | 1,275 | |||||||||||||||
| Gross Profit | 3,668 | 23 | 3,691 | 3,501 | 31 | 3,532 | |||||||||||||||||
| Gross Profit as a % of Sales | 73.2 | % | 0.5 | % | 73.7 | % | 72.8 | % | 0.7 | % | 73.5 | % | |||||||||||
| Marketing, Selling and Administration | 928 | (4 | ) | 924 | 900 | (13 | ) | 887 | |||||||||||||||
|
Advertising and Product Promotion |
214 | -- | 214 | 212 | -- | 212 | |||||||||||||||||
| Total SG&A | 1,142 | (4 | ) | 1,138 | 1,112 | (13 | ) | 1,099 | |||||||||||||||
| SG&A as a % of Sales | 22.8 | % | (0.1 | )% | 22.7 | % | 23.1 | % | (0.2 | )% | 22.9 | % | |||||||||||
| Research and Development | 935 | (103 | ) | 832 | 910 | (55 | ) | 855 | |||||||||||||||
| R&D as a % of Sales | 18.7 | % | (2.1 | )% | 16.6 | % | 18.9 | % | (1.1 | )% | 17.8 | % | |||||||||||
| Operating Margin | 1,591 | 130 | 1,721 | 1,479 | 99 | 1,578 | |||||||||||||||||
| Operating Margin as % of Sales | 31.8 | % | 2.5 | % | 34.3 | % | 30.8 | % | 2.0 | % | 32.8 | % | |||||||||||
| Provision for restructuring, net | 44 | (44 | ) | -- | 11 | (11 | ) | -- | |||||||||||||||
| Equity in net income of affiliates | (82 | ) | -- | (82 | ) | (97 | ) | -- | (97 | ) | |||||||||||||
| Other (income)/expense, net | (138 | ) | 76 | (62 | ) | 113 | (200 | ) | (87 | ) | |||||||||||||
| Earnings before Income Taxes | $ | 1,767 | 98 | $ | 1,865 | $ | 1,452 | 310 | $ | 1,762 | |||||||||||||
| Provision for income taxes | 400 | 84 | 484 | 351 | 86 | 437 | |||||||||||||||||
| Net Earnings | $ | 1,367 | 14 | $ | 1,381 | $ | 1,101 | 224 | $ | 1,325 | |||||||||||||
| Net Earnings – Attributable to Noncontrolling Interest | 381 | 381 | 358 | 358 | |||||||||||||||||||
| Net Earnings – Attributable to BMS | $ | 986 | 14 | $ | 1,000 | $ | 743 | 224 | $ | 967 | |||||||||||||
|
Contingently convertible debt interest expense and |
|||||||||||||||||||||||
|
earnings attributable to unvested shares |
(2 | ) | (2 | ) | (3 | ) | (3 | ) | |||||||||||||||
|
Net Earnings used for Diluted EPS Calc – Attributable |
|||||||||||||||||||||||
|
to BMS |
$ | 984 | 14 | $ | 998 | $ | 740 | 224 | $ | 964 | |||||||||||||
| Avg Shares (Diluted) | 1,714 | 1,714 | 1,725 | 1,725 | |||||||||||||||||||
| Diluted EPS – Attributable to BMS | $ | 0.57 | 0.01 | $ | 0.58 | $ | 0.43 | 0.13 | $ | 0.56 | |||||||||||||
| Net Earnings Attributable to BMS as a % of sales | 19.7 | % | 0.3 | % | 20.0 | % | 15.5 | % | 4.6 | % | 20.1 | % | |||||||||||
| Effective Tax Rate | 22.6 | % | 3.4 | % | 26.0 | % | 24.2 | % | 0.6 | % | 24.8 | % | |||||||||||
|
* Refer to the Specified Items schedules for further details. |
|||||||||||||||||||||||
|
BRISTOL-MYERS SQUIBB COMPANY |
|||||||||
|
NET CASH CALCULATION |
|||||||||
|
AS OF MARCH 31, 2011 AND DECEMBER 31, 2010 |
|||||||||
|
(Unaudited, dollars in millions) |
|||||||||
| March 31, 2011 | December 31, 2010 | ||||||||
| Cash and cash equivalents | $ | 3,405 | $ | 5,033 | |||||
| Marketable securities–current | 3,388 | 2,268 | |||||||
| Marketable securities–long-term | 3,065 | 2,681 | |||||||
| Short-term borrowings | (135 | ) | (117 | ) | |||||
| Long-term debt | (5,276 | ) | (5,328 | ) | |||||
| Net cash | $ | 4,447 | $ | 4,537 | |||||
CONTACT:
Bristol-Myers Squibb Company
Communications
Jennifer Fron Mauer, 609-252-6579
or
Investor Relations
Teri Loxam, 609-252-3368
Timothy Power, 609-252-7509
KEYWORDS: United States North America New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Mental Health Pharmaceutical Diabetes
MEDIA:
| Logo |